CTMX
CytomX Therapeutics, Inc.
There isn't enough reported data to score CTMX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CTMX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
CTMX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CTMX PE Valuation
CTMX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CTMX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CTMX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CTMX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.61 | -253% |
| Q2 2026 | -$0.61 | -209% |
| Q1 2026 | -$0.52 | -208% |
| Q4 2025 | -$0.15 | -139% |
| Q3 2025 | $0.40 | +122% |
| Q2 2025 | $0.56 | +273% |
| Q1 2025 | $0.48 | +129% |
| Q4 2024 | $0.38 | +$0.39 |
CTMX has swung to a loss: it lost $0.61 per share over the past year, after a profit the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CTMX on earnings quality, reporting a profit while its opponent remains loss making.
CTMX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7M | -72% |
| Q2 2026 | $1.4M | -92% |
| Q1 2026 | $10.3M | -80% |
| Q4 2025 | $663K | -98% |
| Q3 2025 | $6M | -82% |
| Q2 2025 | $18.7M | -26% |
| Q1 2025 | $50.9M | +23% |
| Q4 2024 | $38.1M | +43% |
CTMX's revenue has slid since its 2025 peak: $2M last quarter, down 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1392% | -1128 points |
| Q2 2026 | -1677% | -1670 points |
| Q1 2026 | -192% | -236 points |
| Q4 2025 | -4213% | -4259 points |
| Q3 2025 | -264% | -277 points |
| Q2 2025 | -6.9% | +27 points |
| Q1 2025 | 44% | +16 points |
| Q4 2024 | 46% | +49 points |
CTMX's operating margin was −1392% last quarter, down 1128 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CTMX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CTMX on profitability, with a higher operating margin.
CTMX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $16.1M | +$31.5M |
| Q2 2026 | -$18.1M | -$2.3M |
| Q1 2026 | -$25.5M | -$4.4M |
| Q4 2025 | -$23.4M | -$3.5M |
| Q3 2025 | -$15.4M | +$5.3M |
| Q2 2025 | -$15.8M | +$3.9M |
| Q1 2025 | -$21.2M | +$5M |
| Q4 2024 | -$20M | +$2.2M |
CTMX has burned cash in almost every quarter: −$51M over the past year, against −$72M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CTMX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTMX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +167K shares |
| 1 year | +33% | +54.1M shares |
| 3 years | +171% | +138M shares |
| 5 years | +236% | +154M shares |
| Available history | +383% | +174M shares |
CTMX has 219M diluted shares, up 33% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CTMX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CTMX Net Leverage
CTMX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CTMX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.8 | Neutral |
| Stochastic | 7.3 | Oversold |
CTMX's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CTMX PE vs Healthcare Sector
| Metric | CTMX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTMX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CTMX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.38 | 14% below |
| 20 week MA | $2.98 | 32% below |
| 50 week MA | $3.82 | 47% below |
| 100 week MA | $2.87 | 29% below |
| 200 week MA | $2.23 | 8.5% below |
CTMX is in a downtrend: it's below all five of its weekly moving averages, and 8.5% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CTMX on trend strength, trading above more of its moving averages.
CTMX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.54 | $7.42 | -13% |
| 2021 | $7.42 | $4.22 | -43% |
| 2022 | $4.22 | $1.55 | -63% |
| 2023 | $1.55 | $1.55 | 0% |
| 2024 | $1.55 | $1.07 | -31% |
| 2025 | $1.07 | $4.39 | +310% |
| 2026 YTD | $4.39 | $2.04 | -54% |
CTMX's yearly returns have swung widely, from +310% in 2025 to −63% in 2022. It's down 54% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CTMX on returns for 2026, with the stronger performance.